Literature DB >> 29557506

The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.

Marian Christoph Neidert1,2, Daniel Johannes Kowalewski3, Manuela Silginer4, Konstantina Kapolou4, Linus Backert3,5, Lena Katharina Freudenmann3,6, Janet Kerstin Peper3, Ana Marcu3, Sophie Shih-Yüng Wang7,4, Juliane Sarah Walz3,8, Fabian Wolpert4, Hans-Georg Rammensee3,6, Reinhard Henschler9,10, Katrin Lamszus11, Manfred Westphal11, Patrick Roth4, Luca Regli7, Stefan Stevanović3,6, Michael Weller4, Günter Eisele4.   

Abstract

Glioblastoma is the most frequent malignant primary brain tumor. In a hierarchical tumor model, glioblastoma stem-like cells (GSC) play a major role in tumor initiation and maintenance as well as in therapy resistance and recurrence. Thus, targeting this cellular subset may be key to effective immunotherapy. Here, we present a mass spectrometry-based analysis of HLA-presented peptidomes of GSC and glioblastoma patient specimens. Based on the analysis of patient samples (n = 9) and GSC (n = 3), we performed comparative HLA peptidome profiling against a dataset of normal human tissues. Using this immunopeptidome-centric approach we could clearly delineate a subset of naturally presented, GSC-associated HLA ligands, which might serve as highly specific targets for T cell-based immunotherapy. In total, we identified 17 antigens represented by 41 different HLA ligands showing natural and exclusive presentation both on GSC and patient samples. Importantly, in vitro immunogenicity and antigen-specific target cell killing assays suggest these peptides to be epitopes of functional CD8+ T cell responses, thus rendering them prime candidates for antigen-specific immunotherapy of glioblastoma.

Entities:  

Keywords:  GSC; Glioblastoma; Glioblastoma stem-like cells; HLA ligand; Immunotherapy; Tumor-associated antigen

Mesh:

Substances:

Year:  2018        PMID: 29557506     DOI: 10.1007/s00401-018-1836-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  18 in total

Review 1.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

2.  Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Authors:  Hans-Georg Wirsching; Huajia Zhang; Frank Szulzewsky; Sonali Arora; Paola Grandi; Patrick J Cimino; Nduka Amankulor; Jean S Campbell; Lisa McFerrin; Siobhan S Pattwell; Chibawanye Ene; Alexandra Hicks; Michael Ball; James Yan; Jenny Zhang; Debrah Kumasaka; Robert H Pierce; Michael Weller; Mitchell Finer; Christophe Quéva; Joseph C Glorioso; A McGarry Houghton; Eric C Holland
Journal:  JCI Insight       Date:  2019-07-11

3.  Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.

Authors:  Michael Ghosh; Marion Gauger; Ana Marcu; Annika Nelde; Monika Denk; Heiko Schuster; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Mol Cell Proteomics       Date:  2020-01-14       Impact factor: 5.911

Review 4.  Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.

Authors:  Laura Santambrogio; Hans-Georg Rammensee
Journal:  Immunogenetics       Date:  2018-10-20       Impact factor: 2.846

5.  Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.

Authors:  Annika Nelde; Yacine Maringer; Tatjana Bilich; Helmut R Salih; Malte Roerden; Jonas S Heitmann; Ana Marcu; Jens Bauer; Marian C Neidert; Claudio Denzlinger; Gerald Illerhaus; Walter Erich Aulitzky; Hans-Georg Rammensee; Juliane S Walz
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

Review 6.  The adaptive transition of glioblastoma stem cells and its implications on treatments.

Authors:  Zeyu Wang; Hao Zhang; Shengchao Xu; Zhixiong Liu; Quan Cheng
Journal:  Signal Transduct Target Ther       Date:  2021-03-23

Review 7.  Putting Proteomics Into Immunotherapy for Glioblastoma.

Authors:  Liangyu Chen; Di Qin; Xinyu Guo; Qixue Wang; Jie Li
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

Review 8.  Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.

Authors:  Karina Biserova; Arvids Jakovlevs; Romans Uljanovs; Ilze Strumfa
Journal:  Cells       Date:  2021-03-11       Impact factor: 6.600

9.  Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.

Authors:  Anja Tatjana Teck; Sabrina Urban; Petra Quass; Annika Nelde; Heiko Schuster; Anne Letsch; Antonia Busse; Juliane Sarah Walz; Ulrich Keilholz; Sebastian Ochsenreither
Journal:  Cancer Immunol Immunother       Date:  2020-03-10       Impact factor: 6.968

Review 10.  Tumor-Specific T Cell Activation in Malignant Brain Tumors.

Authors:  Malte Mohme; Marian Christoph Neidert
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.